The EvA study: Aims and strategy

Loems Ziegler-Heitbrock, Marion Frankenberger, Irene Heimbeck, Dorothe Burggraf, Matthias Wjst, Karl Häussinger, Chris Brightling, Sumit Gupta, David Parr, Deepak Subramanian, Dave Singh, Umme Kolsum, Piera Boschetto, Alfredo Potena, Dorota Gorecka, Adam Nowinski, I. Barta, B. Döme, J. Strausz, Timm GreulichClaus Vogelmeier, Robert Bals, Jens M. Hohlfeld, Tobias Welte, Per Venge, Ivo Gut, Anne Boland, Robert Olaso, Jörg Hager, Pieter Hiemstra, Klaus F. Rabe, Martina Unmußig, Joachim Müller-Quernheim, Antje Prasse

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The EvA study is a European Union-funded project under the Seventh Framework Programme (FP7), which aims at defining new markers for chronic obstructive pulmonary disease (COPD) and its subtypes. The acronym is derived from emphysema versus airway disease, indicating that the project targets these two main phenotypes of the disease. The EvA study is based on the concept that emphysema and airway disease are governed by different pathophysiological processes, are driven by different genes and have differential gene expression in the lung. To define these genes, patients and non-COPD controls are recruited for clinical examination, lung function analysis and computed tomography (CT) of the lung. CT scans are used to define the phenotypes based on lung density and airway wall thickness. This is followed by bronchoscopy in order to obtain samples from the airways and the alveoli. These tissue samples, along with blood samples, are then subjected to genome-wide expression and association analysis and markers linked to the phenotypes are identified. The population of the EvA study is different from other COPD study populations, since patients with current oral glucocorticoids, antibiotics and exacerbations or current smokers are excluded, such that the signals detected in the molecular analysis are due to the distinct inflammatory process of emphysema and airway disease in COPD. Copyright

Original languageEnglish
Pages (from-to)823-829
Number of pages7
JournalEuropean Respiratory Journal
Volume40
Issue number4
DOIs
Publication statusPublished - Oct 1 2012

Fingerprint

Emphysema
Chronic Obstructive Pulmonary Disease
Lung
Phenotype
Tomography
Obstructive Lung Diseases
Genome-Wide Association Study
Bronchoscopy
European Union
Glucocorticoids
Population
Genes
Anti-Bacterial Agents
Gene Expression

Keywords

  • Airway inflammation
  • Bronchoalveloar lavage
  • Computed tomography
  • Emphysema

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Ziegler-Heitbrock, L., Frankenberger, M., Heimbeck, I., Burggraf, D., Wjst, M., Häussinger, K., ... Prasse, A. (2012). The EvA study: Aims and strategy. European Respiratory Journal, 40(4), 823-829. https://doi.org/10.1183/09031936.00142811

The EvA study : Aims and strategy. / Ziegler-Heitbrock, Loems; Frankenberger, Marion; Heimbeck, Irene; Burggraf, Dorothe; Wjst, Matthias; Häussinger, Karl; Brightling, Chris; Gupta, Sumit; Parr, David; Subramanian, Deepak; Singh, Dave; Kolsum, Umme; Boschetto, Piera; Potena, Alfredo; Gorecka, Dorota; Nowinski, Adam; Barta, I.; Döme, B.; Strausz, J.; Greulich, Timm; Vogelmeier, Claus; Bals, Robert; Hohlfeld, Jens M.; Welte, Tobias; Venge, Per; Gut, Ivo; Boland, Anne; Olaso, Robert; Hager, Jörg; Hiemstra, Pieter; Rabe, Klaus F.; Unmußig, Martina; Müller-Quernheim, Joachim; Prasse, Antje.

In: European Respiratory Journal, Vol. 40, No. 4, 01.10.2012, p. 823-829.

Research output: Contribution to journalArticle

Ziegler-Heitbrock, L, Frankenberger, M, Heimbeck, I, Burggraf, D, Wjst, M, Häussinger, K, Brightling, C, Gupta, S, Parr, D, Subramanian, D, Singh, D, Kolsum, U, Boschetto, P, Potena, A, Gorecka, D, Nowinski, A, Barta, I, Döme, B, Strausz, J, Greulich, T, Vogelmeier, C, Bals, R, Hohlfeld, JM, Welte, T, Venge, P, Gut, I, Boland, A, Olaso, R, Hager, J, Hiemstra, P, Rabe, KF, Unmußig, M, Müller-Quernheim, J & Prasse, A 2012, 'The EvA study: Aims and strategy', European Respiratory Journal, vol. 40, no. 4, pp. 823-829. https://doi.org/10.1183/09031936.00142811
Ziegler-Heitbrock L, Frankenberger M, Heimbeck I, Burggraf D, Wjst M, Häussinger K et al. The EvA study: Aims and strategy. European Respiratory Journal. 2012 Oct 1;40(4):823-829. https://doi.org/10.1183/09031936.00142811
Ziegler-Heitbrock, Loems ; Frankenberger, Marion ; Heimbeck, Irene ; Burggraf, Dorothe ; Wjst, Matthias ; Häussinger, Karl ; Brightling, Chris ; Gupta, Sumit ; Parr, David ; Subramanian, Deepak ; Singh, Dave ; Kolsum, Umme ; Boschetto, Piera ; Potena, Alfredo ; Gorecka, Dorota ; Nowinski, Adam ; Barta, I. ; Döme, B. ; Strausz, J. ; Greulich, Timm ; Vogelmeier, Claus ; Bals, Robert ; Hohlfeld, Jens M. ; Welte, Tobias ; Venge, Per ; Gut, Ivo ; Boland, Anne ; Olaso, Robert ; Hager, Jörg ; Hiemstra, Pieter ; Rabe, Klaus F. ; Unmußig, Martina ; Müller-Quernheim, Joachim ; Prasse, Antje. / The EvA study : Aims and strategy. In: European Respiratory Journal. 2012 ; Vol. 40, No. 4. pp. 823-829.
@article{e34035ea639948e9938b0bf57beeac0f,
title = "The EvA study: Aims and strategy",
abstract = "The EvA study is a European Union-funded project under the Seventh Framework Programme (FP7), which aims at defining new markers for chronic obstructive pulmonary disease (COPD) and its subtypes. The acronym is derived from emphysema versus airway disease, indicating that the project targets these two main phenotypes of the disease. The EvA study is based on the concept that emphysema and airway disease are governed by different pathophysiological processes, are driven by different genes and have differential gene expression in the lung. To define these genes, patients and non-COPD controls are recruited for clinical examination, lung function analysis and computed tomography (CT) of the lung. CT scans are used to define the phenotypes based on lung density and airway wall thickness. This is followed by bronchoscopy in order to obtain samples from the airways and the alveoli. These tissue samples, along with blood samples, are then subjected to genome-wide expression and association analysis and markers linked to the phenotypes are identified. The population of the EvA study is different from other COPD study populations, since patients with current oral glucocorticoids, antibiotics and exacerbations or current smokers are excluded, such that the signals detected in the molecular analysis are due to the distinct inflammatory process of emphysema and airway disease in COPD. Copyright",
keywords = "Airway inflammation, Bronchoalveloar lavage, Computed tomography, Emphysema",
author = "Loems Ziegler-Heitbrock and Marion Frankenberger and Irene Heimbeck and Dorothe Burggraf and Matthias Wjst and Karl H{\"a}ussinger and Chris Brightling and Sumit Gupta and David Parr and Deepak Subramanian and Dave Singh and Umme Kolsum and Piera Boschetto and Alfredo Potena and Dorota Gorecka and Adam Nowinski and I. Barta and B. D{\"o}me and J. Strausz and Timm Greulich and Claus Vogelmeier and Robert Bals and Hohlfeld, {Jens M.} and Tobias Welte and Per Venge and Ivo Gut and Anne Boland and Robert Olaso and J{\"o}rg Hager and Pieter Hiemstra and Rabe, {Klaus F.} and Martina Unmu{\ss}ig and Joachim M{\"u}ller-Quernheim and Antje Prasse",
year = "2012",
month = "10",
day = "1",
doi = "10.1183/09031936.00142811",
language = "English",
volume = "40",
pages = "823--829",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "4",

}

TY - JOUR

T1 - The EvA study

T2 - Aims and strategy

AU - Ziegler-Heitbrock, Loems

AU - Frankenberger, Marion

AU - Heimbeck, Irene

AU - Burggraf, Dorothe

AU - Wjst, Matthias

AU - Häussinger, Karl

AU - Brightling, Chris

AU - Gupta, Sumit

AU - Parr, David

AU - Subramanian, Deepak

AU - Singh, Dave

AU - Kolsum, Umme

AU - Boschetto, Piera

AU - Potena, Alfredo

AU - Gorecka, Dorota

AU - Nowinski, Adam

AU - Barta, I.

AU - Döme, B.

AU - Strausz, J.

AU - Greulich, Timm

AU - Vogelmeier, Claus

AU - Bals, Robert

AU - Hohlfeld, Jens M.

AU - Welte, Tobias

AU - Venge, Per

AU - Gut, Ivo

AU - Boland, Anne

AU - Olaso, Robert

AU - Hager, Jörg

AU - Hiemstra, Pieter

AU - Rabe, Klaus F.

AU - Unmußig, Martina

AU - Müller-Quernheim, Joachim

AU - Prasse, Antje

PY - 2012/10/1

Y1 - 2012/10/1

N2 - The EvA study is a European Union-funded project under the Seventh Framework Programme (FP7), which aims at defining new markers for chronic obstructive pulmonary disease (COPD) and its subtypes. The acronym is derived from emphysema versus airway disease, indicating that the project targets these two main phenotypes of the disease. The EvA study is based on the concept that emphysema and airway disease are governed by different pathophysiological processes, are driven by different genes and have differential gene expression in the lung. To define these genes, patients and non-COPD controls are recruited for clinical examination, lung function analysis and computed tomography (CT) of the lung. CT scans are used to define the phenotypes based on lung density and airway wall thickness. This is followed by bronchoscopy in order to obtain samples from the airways and the alveoli. These tissue samples, along with blood samples, are then subjected to genome-wide expression and association analysis and markers linked to the phenotypes are identified. The population of the EvA study is different from other COPD study populations, since patients with current oral glucocorticoids, antibiotics and exacerbations or current smokers are excluded, such that the signals detected in the molecular analysis are due to the distinct inflammatory process of emphysema and airway disease in COPD. Copyright

AB - The EvA study is a European Union-funded project under the Seventh Framework Programme (FP7), which aims at defining new markers for chronic obstructive pulmonary disease (COPD) and its subtypes. The acronym is derived from emphysema versus airway disease, indicating that the project targets these two main phenotypes of the disease. The EvA study is based on the concept that emphysema and airway disease are governed by different pathophysiological processes, are driven by different genes and have differential gene expression in the lung. To define these genes, patients and non-COPD controls are recruited for clinical examination, lung function analysis and computed tomography (CT) of the lung. CT scans are used to define the phenotypes based on lung density and airway wall thickness. This is followed by bronchoscopy in order to obtain samples from the airways and the alveoli. These tissue samples, along with blood samples, are then subjected to genome-wide expression and association analysis and markers linked to the phenotypes are identified. The population of the EvA study is different from other COPD study populations, since patients with current oral glucocorticoids, antibiotics and exacerbations or current smokers are excluded, such that the signals detected in the molecular analysis are due to the distinct inflammatory process of emphysema and airway disease in COPD. Copyright

KW - Airway inflammation

KW - Bronchoalveloar lavage

KW - Computed tomography

KW - Emphysema

UR - http://www.scopus.com/inward/record.url?scp=84867122301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867122301&partnerID=8YFLogxK

U2 - 10.1183/09031936.00142811

DO - 10.1183/09031936.00142811

M3 - Article

C2 - 22441733

AN - SCOPUS:84867122301

VL - 40

SP - 823

EP - 829

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 4

ER -